Cargando…

New onset severe ulcerative colitis following Ixekizumab therapy

Ixekizumab is one of the three biologic agents including Secukinumab and Brodalumab that targets the Interleukin-17 (IL-17) pathway to reduce inflammation in psoriasis and ankylosing spondylitis. In this report we present the case of 42-year-old woman, who was diagnosed with psoriasis and psoriatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Morosanu, Alina Mihaela, Mihai, Ioana Ruxandra, Rezus, Ioana Irina, Gavrilescu, Otilia, Dranga, Mihaela, Prelipcean, Cristina Cijevschi, Mihai, Catalina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: UMF “Gr. T. Popa” Iasi Publishing House 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769074/
https://www.ncbi.nlm.nih.gov/pubmed/36628163
http://dx.doi.org/10.22551/2022.37.0904.10227
_version_ 1784854308739612672
author Morosanu, Alina Mihaela
Mihai, Ioana Ruxandra
Rezus, Ioana Irina
Gavrilescu, Otilia
Dranga, Mihaela
Prelipcean, Cristina Cijevschi
Mihai, Catalina
author_facet Morosanu, Alina Mihaela
Mihai, Ioana Ruxandra
Rezus, Ioana Irina
Gavrilescu, Otilia
Dranga, Mihaela
Prelipcean, Cristina Cijevschi
Mihai, Catalina
author_sort Morosanu, Alina Mihaela
collection PubMed
description Ixekizumab is one of the three biologic agents including Secukinumab and Brodalumab that targets the Interleukin-17 (IL-17) pathway to reduce inflammation in psoriasis and ankylosing spondylitis. In this report we present the case of 42-year-old woman, who was diagnosed with psoriasis and psoriatic arthritis. One week after first administration of Ixekizumab, she developed diffuse abdominal pain, bloody diarrhea (7-8 stools/day) and fever. Following imaging (colonoscopy, computed tomography) and laboratory investigations, she was diagnosed with acute severe ulcerative colitis complicated with toxic megacolon. The medical treatment (first corticotherapy, then infliximab) has failed and the patient needed emergency colectomy. Based on the immunological mechanisms and the observation from other studies, Ixekizumab should be considered an etiology for new-onset inflammatory bowel disease.
format Online
Article
Text
id pubmed-9769074
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher UMF “Gr. T. Popa” Iasi Publishing House
record_format MEDLINE/PubMed
spelling pubmed-97690742023-01-09 New onset severe ulcerative colitis following Ixekizumab therapy Morosanu, Alina Mihaela Mihai, Ioana Ruxandra Rezus, Ioana Irina Gavrilescu, Otilia Dranga, Mihaela Prelipcean, Cristina Cijevschi Mihai, Catalina Arch Clin Cases Case Report Ixekizumab is one of the three biologic agents including Secukinumab and Brodalumab that targets the Interleukin-17 (IL-17) pathway to reduce inflammation in psoriasis and ankylosing spondylitis. In this report we present the case of 42-year-old woman, who was diagnosed with psoriasis and psoriatic arthritis. One week after first administration of Ixekizumab, she developed diffuse abdominal pain, bloody diarrhea (7-8 stools/day) and fever. Following imaging (colonoscopy, computed tomography) and laboratory investigations, she was diagnosed with acute severe ulcerative colitis complicated with toxic megacolon. The medical treatment (first corticotherapy, then infliximab) has failed and the patient needed emergency colectomy. Based on the immunological mechanisms and the observation from other studies, Ixekizumab should be considered an etiology for new-onset inflammatory bowel disease. UMF “Gr. T. Popa” Iasi Publishing House 2022-12-19 /pmc/articles/PMC9769074/ /pubmed/36628163 http://dx.doi.org/10.22551/2022.37.0904.10227 Text en https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Morosanu, Alina Mihaela
Mihai, Ioana Ruxandra
Rezus, Ioana Irina
Gavrilescu, Otilia
Dranga, Mihaela
Prelipcean, Cristina Cijevschi
Mihai, Catalina
New onset severe ulcerative colitis following Ixekizumab therapy
title New onset severe ulcerative colitis following Ixekizumab therapy
title_full New onset severe ulcerative colitis following Ixekizumab therapy
title_fullStr New onset severe ulcerative colitis following Ixekizumab therapy
title_full_unstemmed New onset severe ulcerative colitis following Ixekizumab therapy
title_short New onset severe ulcerative colitis following Ixekizumab therapy
title_sort new onset severe ulcerative colitis following ixekizumab therapy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769074/
https://www.ncbi.nlm.nih.gov/pubmed/36628163
http://dx.doi.org/10.22551/2022.37.0904.10227
work_keys_str_mv AT morosanualinamihaela newonsetsevereulcerativecolitisfollowingixekizumabtherapy
AT mihaiioanaruxandra newonsetsevereulcerativecolitisfollowingixekizumabtherapy
AT rezusioanairina newonsetsevereulcerativecolitisfollowingixekizumabtherapy
AT gavrilescuotilia newonsetsevereulcerativecolitisfollowingixekizumabtherapy
AT drangamihaela newonsetsevereulcerativecolitisfollowingixekizumabtherapy
AT prelipceancristinacijevschi newonsetsevereulcerativecolitisfollowingixekizumabtherapy
AT mihaicatalina newonsetsevereulcerativecolitisfollowingixekizumabtherapy